Contract Award

Physiomics PLC

05 December 2024

 

5 December 2024

Physiomics plc

("Physiomics" or the "Company")

Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce it has been awarded a new contract with a long-standing, globally recognised pharmaceutical client. The project, valued at £157k, will leverage Physiomics' expertise in Pharmacokinetic-Pharmacodynamic ("PKPD") modelling to inform critical pre-clinical and clinical dosing and scheduling decisions for a novel cancer treatment combination. Delivery of the project is expected to complete within the next 12 months.

This new project represents a significant expansion of the ongoing collaboration between Physiomics and its client, marking the first incorporation of an Antibody-Drug Conjugate ("ADC") into the company's Virtual Tumour ("VT") modelling platform. ADCs are a rapidly advancing class of targeted therapies in oncology, offering enhanced precision by enabling tumour specific delivery of potent cytotoxic payloads. This project positions Physiomics at the forefront of this exciting field of drug development.

Dr Peter Sargent, CEO of Physiomics, commented:

"This new contract demonstrates the strength and longevity of our collaboration with one of the world's leading pharmaceutical companies and reflects their trust in our modelling expertise to support the development of advanced therapies. We are particularly excited to expand our Virtual Tumour platform to include ADCs - a hot topic in cancer treatment right now. We look forward to starting work on this project and continue to demonstrate our expertise across a diverse range of therapeutic approaches."

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

[phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

END